Legacy Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-01-2025
- Paid Up Capital ₹ 0.10 M
as on 02-01-2025
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 Cr
as on 02-01-2025
- Revenue -10.94%
(FY 2021)
- Profit 24.81%
(FY 2021)
- Ebitda 28.08%
(FY 2021)
- Net Worth 32.46%
(FY 2021)
- Total Assets 2.33%
(FY 2021)
About Legacy Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 Cr.
Ram Magar, Nilesh Aparajit, and Dhananjay Kulkarni serve as directors at the Company.
- CIN/LLPIN
U24290PN2016PTC158159
- Company No.
158159
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jan 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Legacy Pharmaceuticals Private Limited offer?
Legacy Pharmaceuticals Private Limited offers a wide range of products and services, including Respiratory System Drugs, Anti Asthma Drug, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Aceclofenac, Anti Inflammatory Drugs.
Who are the key members and board of directors at Legacy Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Magar  | Additional Director | 20-Sep-2024 | Current |
| Nilesh Aparajit | Director | 29-Jan-2016 | Current |
| Dhananjay Kulkarni | Additional Director | 10-Jun-2021 | Current |
Financial Performance of Legacy Pharmaceuticals.
Legacy Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 10.94% decrease. The company also saw a substantial improvement in profitability, with a 24.81% increase in profit. The company's net worth Soared by an impressive increase of 32.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Legacy Pharmaceuticals?
In 2021, Legacy Pharmaceuticals had a promoter holding of 51.00% and a public holding of 49.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Sep 2024 | ₹1.50 Cr | Open |
How Many Employees Work at Legacy Pharmaceuticals?
Legacy Pharmaceuticals has a workforce of 29 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Legacy Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Legacy Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
